Indication
Small Intestinal Carcinoma
1 clinical trial
1 product
Clinical trial
A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel AdenocarcinomasStatus: Active (not recruiting), Estimated PCD: 2019-01-31
Product
Pembrolizumab